No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
LGND240517P80000
- 0.40
- -1.75-81.40%
15min DelayClose May 13 15:59 ET
0.40High0.40Low
0.40Open2.15Pre Close1 Volume14 Open Interest80.00Strike Price40.00Turnover47.31%IV-5.26%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier4DDays to Expiry0.40Time Value100Contract SizeAmericanOptions Type-0.1543Delta0.0559Gamma240.20Leverage Ratio-0.1191Theta-0.0014Rho-37.06Eff Leverage0.0213Vega
Intraday
- 5D
- 1D
News
Form 144 | Ligand Pharmaceuticals(LGND.US) Officer Proposes to Sell 434.5K in Common Stocks
SEC FILLINGS DISCLOSED/ May 13, $Ligand Pharmaceuticals(LGND.US)$、$LIGAND PHARMACEUTICAL INC(LGNDZ.US)$、$LIGAND PHARMACEUTICAL INC(LGNXZ.US)$、$LIGAND PHARMACEUTICAL INC(LGNYZ.US)$、$LIGAND PHARMACEUTIC
Ligand Pharmaceuticals(LGND.US) Officer Sells US$830.45K in Common Stock
$Ligand Pharmaceuticals(LGND.US)$ Officer Reardon Andrew sold 10,000 shares of common stock on May 9, 2024 at an average price of $83.0449 for a total value of $830.45K.Source: Announcement What is st
Ligand Pharmaceuticals Insider Sold Shares Worth $830,449, According to a Recent SEC Filing
Andrew Reardon, Chief Legal Officer, on May 09, 2024, sold 10,000 shares in Ligand Pharmaceuticals (LGND) for $830,449. Following the Form 4 filing with the SEC, Reardon has control over a total of 22
Form 144 | Ligand Pharmaceuticals(LGND.US) Officer Proposes to Sell 830.45K in Common Stocks
SEC FILLINGS DISCLOSED/ May 9, $Ligand Pharmaceuticals(LGND.US)$、$LIGAND PHARMACEUTICAL INC(LGNDZ.US)$、$LIGAND PHARMACEUTICAL INC(LGNXZ.US)$、$LIGAND PHARMACEUTICAL INC(LGNYZ.US)$、$LIGAND PHARMACEUTICA
10% Of This Ligand Pharmaceuticals Insider's Holdings Were Sold
From what we can see, insiders were net sellers in Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND ) during the past 12 months. That is, insiders sold the stock in greater numbers than they purchas
10-Q: Quarterly report
Comments
Ligand Pharmaceuticals' key financial indicators are inconsistent, raising questions about the sustainability of its current share price momentum. The company's low ROE and declining net income, along with shrinking earnings despite retaining all profits, suggest potential issues with its business operations or capital allocation.
Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?
$Viking Therapeutics (VKTX.US)$skyrocketed 77% after positive drug trial news Tuesday, leading to what proved to be a strong morning for pharmaceutical stocks.
Here are some top stocks in the sector climbing on drug trial and earnings news:
$Janux Therapeutics (JANX.US)$shares shot up 205% to $36.00 after the company announced updated clinical data for both of its clinical programs, reaching over $1.50B in market cap.
$Ligand Pharmaceuticals (LGND.US)$gained 23%...
Here are some top stocks in the sector climbing on drug trial and earnings news:
$Janux Therapeutics (JANX.US)$shares shot up 205% to $36.00 after the company announced updated clinical data for both of its clinical programs, reaching over $1.50B in market cap.
$Ligand Pharmaceuticals (LGND.US)$gained 23%...
6
Insider selling at Ligand Pharmaceuticals, particularly at current share price, raises caution. Modest insider ownership indicates some alignment with shareholders, but lack of recent insider transactions doesn't raise immediate concerns.
Ligand Pharmaceuticals' high P/E ratio may be plausible with outstanding growth. Its promising future earnings outlook may prevent investors from selling stocks. Unless earnings decline, the current P/E ratio could support the share price.
Soticlestat's potential in treating Lennox-Gastaut and Dravet syndromes is backed by Ovid and Ligand's deal. Ligand sees the deal aligning with its strategy of investing in solutions answering high unmet needs, promising high-margin growth for its investors.
Read more